In lung cancer, triptolide enhances the efficacy of EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib, and icotinib, which are standard targeted therapies for NSCLC with EGFR mutation cell carcinoma [988]. Here, EGFR is linked to lung cancer.